MXPA05013769A - Variantes del dominio gla del factor vii o viia. - Google Patents

Variantes del dominio gla del factor vii o viia.

Info

Publication number
MXPA05013769A
MXPA05013769A MXPA05013769A MXPA05013769A MXPA05013769A MX PA05013769 A MXPA05013769 A MX PA05013769A MX PA05013769 A MXPA05013769 A MX PA05013769A MX PA05013769 A MXPA05013769 A MX PA05013769A MX PA05013769 A MXPA05013769 A MX PA05013769A
Authority
MX
Mexico
Prior art keywords
factor vii
amino acid
gla domain
domain variants
human factor
Prior art date
Application number
MXPA05013769A
Other languages
English (en)
Inventor
Claus Bornaes
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA05013769A publication Critical patent/MXPA05013769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las variantes del dominio Gla del factor VII de humano o del factor VIIa de humano, que comprenden 1-5 modificaciones de aminoacidos en relacion con el factor VII de humano o el factor VIIa de humano, en donde un residuo de aminoacido hidrofobo ha sido introducido mediante sustitucion en la posicion 34, o que tiene una sustitucion de aminoacido en la posicion 36, o que tienen sustituciones de aminoacidos en las posiciones 10 y 32 y al menos una sustitucion adicional de aminoacido en una posicion seleccionada a partir de 74, 77 y 116.
MXPA05013769A 2003-06-19 2004-06-18 Variantes del dominio gla del factor vii o viia. MXPA05013769A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47978003P 2003-06-19 2003-06-19
DKPA200400930 2004-06-15
PCT/DK2004/000428 WO2004111242A1 (en) 2003-06-19 2004-06-18 FACTOR VII OR VIIa GLA DOMAIN VARIANTS

Publications (1)

Publication Number Publication Date
MXPA05013769A true MXPA05013769A (es) 2006-03-08

Family

ID=33553697

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013769A MXPA05013769A (es) 2003-06-19 2004-06-18 Variantes del dominio gla del factor vii o viia.

Country Status (24)

Country Link
US (5) US20050164932A1 (es)
EP (1) EP1644504B8 (es)
JP (2) JP4915918B2 (es)
KR (1) KR101191779B1 (es)
CN (1) CN1839203B (es)
AT (1) ATE458057T1 (es)
AU (2) AU2004247799B2 (es)
BR (1) BRPI0411650A (es)
CA (1) CA2529828C (es)
CY (1) CY1109984T1 (es)
DE (1) DE602004025576D1 (es)
DK (1) DK1644504T3 (es)
ES (1) ES2338425T3 (es)
HK (1) HK1095357A1 (es)
HR (1) HRP20100264T1 (es)
IL (1) IL172364A (es)
MX (1) MXPA05013769A (es)
NZ (2) NZ544728A (es)
PL (1) PL1644504T3 (es)
PT (1) PT1644504E (es)
RU (1) RU2373282C2 (es)
SI (1) SI1644504T1 (es)
WO (1) WO2004111242A1 (es)
ZA (1) ZA200600539B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
SI1644504T1 (sl) * 2003-06-19 2010-06-30 Bayer Healthcare Llc Variante Gla domene faktorja VII ali VIIa
RU2396347C2 (ru) 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
PL1907540T3 (pl) * 2005-07-22 2013-05-31 Bayer Healthcare Llc Aktywacja czynnika VII w roztworze
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
WO2008127702A2 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
BR112015015182B1 (pt) * 2012-12-24 2023-12-26 Coagulant Therapeutics Corporation Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos
ES2945160T3 (es) * 2013-03-15 2023-06-28 Gladiator Biosciences Inc Dominios Gla como agentes terapéuticos
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
EP3442554A4 (en) * 2016-04-14 2019-12-04 Iconic Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION
EA201990255A1 (ru) 2016-07-11 2019-07-31 Опко Байолоджикс Лтд Фактор свертывания крови vii пролонгированного действия и способы его получения
KR20200050975A (ko) 2017-09-05 2020-05-12 글래디에이터 바이오사이언시즈 인코포레이티드 엑소좀의 표적화 방법
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
CA2073859A1 (en) 1990-01-26 1991-07-27 Falko-Guenter Falkner Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
EP1479395A1 (en) 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
DK0699075T3 (da) 1993-05-21 2002-03-11 Novo Nordisk As Modificeret faktor VII
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
WO1998020118A1 (en) * 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Modified protein c and methods of use thereof
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
CN1325443A (zh) 1998-10-30 2001-12-05 诺沃奇梅兹有限公司 具有减弱的变应原性的糖基化蛋白
ATE390441T1 (de) 1998-10-30 2008-04-15 Novozymes As Niedrigallergene proteinvarianten
JP4463988B2 (ja) 1998-11-06 2010-05-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子の生産方法
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2001287550B2 (en) 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
US7176288B2 (en) * 2000-09-13 2007-02-13 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
WO2002029083A2 (en) 2000-10-02 2002-04-11 Novo Nordisk A/S Industrial-scale serum-free production of recombinant proteins in mammalian cells
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
BR0208203A (pt) 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
WO2003027147A2 (en) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP1451315B1 (en) 2001-11-02 2014-05-21 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
SI1644504T1 (sl) 2003-06-19 2010-06-30 Bayer Healthcare Llc Variante Gla domene faktorja VII ali VIIa

Also Published As

Publication number Publication date
US8987202B2 (en) 2015-03-24
US7807638B2 (en) 2010-10-05
US20060241041A1 (en) 2006-10-26
AU2004247799A1 (en) 2004-12-23
HRP20100264T1 (hr) 2010-08-31
PL1644504T3 (pl) 2010-08-31
AU2010200793A1 (en) 2010-03-25
CA2529828A1 (en) 2004-12-23
WO2004111242A1 (en) 2004-12-23
JP2012105650A (ja) 2012-06-07
US20070117756A1 (en) 2007-05-24
KR20060022283A (ko) 2006-03-09
BRPI0411650A (pt) 2006-08-08
EP1644504B8 (en) 2010-06-02
AU2010200793B2 (en) 2013-04-04
ATE458057T1 (de) 2010-03-15
PT1644504E (pt) 2010-03-22
CA2529828C (en) 2013-01-15
DE602004025576D1 (de) 2010-04-01
CN1839203A (zh) 2006-09-27
RU2373282C2 (ru) 2009-11-20
JP4915918B2 (ja) 2012-04-11
US20050164932A1 (en) 2005-07-28
AU2004247799B2 (en) 2009-12-03
EP1644504B1 (en) 2010-02-17
ZA200600539B (en) 2006-12-27
SI1644504T1 (sl) 2010-06-30
ES2338425T3 (es) 2010-05-07
JP5580283B2 (ja) 2014-08-27
CY1109984T1 (el) 2014-09-10
EP1644504A1 (en) 2006-04-12
HK1095357A1 (en) 2007-05-04
RU2006101391A (ru) 2006-06-10
NZ573412A (en) 2010-09-30
JP2006527982A (ja) 2006-12-14
US20060252128A1 (en) 2006-11-09
DK1644504T3 (da) 2010-05-25
KR101191779B1 (ko) 2013-01-14
US20060240526A1 (en) 2006-10-26
CN1839203B (zh) 2011-11-16
IL172364A (en) 2014-01-30
NZ544728A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
IL172364A (en) Variant of vii or viia factor at gla site
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
WO2003104199A3 (en) ORGANIC CATALYST WITH IMPROVED SOLUBILITY
IL172773A0 (en) Formulations for the treatment of arhritis conditions
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
MXPA05001727A (es) Composiciones y proceso para suministrar un aditivo.
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
GB0111186D0 (en) Novel compounds
MXPA04002636A (es) Barra de tocador teniendo un acidificador latente.
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
MXPA03009548A (es) Arilsulfonamidas como agentes antivirales.
AU2003294785A1 (en) Hair treatment compositions
MX2007011327A (es) Empleo de 5'-metiltioadenosina (mta) en la prevencion y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes.
MXPA03011128A (es) Composicion de sabor y fragancia.
BRPI0408446A (pt) tablete de limpeza
MXPA05012742A (es) Composiciones de tratamiento para el cabello.
IN2009CN00831A (es)
MXPA03001986A (es) Composiciones antitromboticas.
MXPA05012605A (es) Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
MX2007005314A (es) Cetoles espirociclicos y su uso.
WO2004022657A3 (de) Verstärkung der resorption von substanzen über die haut und schleimhaut
DE60220504D1 (en) Tryptasehemmer
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor

Legal Events

Date Code Title Description
FG Grant or registration